Pelareorep - Oncolytics Biotech
Alternative Names: AN-1004; PO-BB0209; REOLYSIN; Reosyn; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus; Wild-type reovirus - Oncolytics BiotechLatest Information Update: 02 Jan 2025
Price :
$50 *
At a glance
- Originator Oncolytics Biotech
- Developer Adlai Nortye; Canadian Cancer Society Research Institute; Mayo Clinic; National Cancer Institute (USA); Oncolytics Biotech; PrECOG; Roche; University of Leeds; University of Southern California
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer; Head and neck cancer
- Phase II Brain cancer; Colorectal cancer; Fallopian tube cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Sarcoma
- Phase I/II Anal cancer; Glioma; Multiple myeloma
- Preclinical Acute myeloid leukaemia
- No development reported Glioblastoma; Liver cancer; Solid tumours
Most Recent Events
- 23 Dec 2024 Oncolytics Biotech plans a registrational study in Pancreatic cancer (First line therapy, Combination therapy) in 2025
- 23 Dec 2024 Oncolytics Biotech plans a registration-enabling trial for HR+/HER2- Breast cancer (Metastatic disease, Combination therapy) in H2 2025
- 28 Nov 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV)